{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2020"],"condition":["Solid Tumor","Carcinoma, Transitional Cell","Head and Neck Cancer","Colorectal Cancer","Urothelial Carcinoma","Pancreatic Cancer","Head and Neck Neoplasms","Neoplasm Metastasis","Colon cancer","Colorectal Neoplasms","Solid tumors","Pancreatic Neoplasms","Metastatic Cancer"],"disease":["Solid Tumor","Carcinoma, Transitional Cell","Colorectal Cancer","Urothelial Carcinoma","Head And Neck Neoplasms","Pancreatic Cancer","Neoplasm Metastasis","Colon Cancer","Colorectal Neoplasms","Head And Neck Cancer","Pancreatic Neoplasms","Metastatic Cancer","Solid Tumors"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2360612"],"location":["United States"],"study_start_month":["12"],"keyword":["Gemcitabine","Bile duct cancer","Paclitaxel","Tislelizumab","Combination therapy"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors","description":"A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors","dates":{"creation":"2020-12-15"},"accession":"2360612","cross_references":{"ClinicalTrials___gov":["NCT04666688"]}}